• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The Clinical Presentation and Immunology of Viral Pneumonia and Implications for Management of Coronavirus Disease 2019.病毒性肺炎的临床表现与免疫学及对2019冠状病毒病管理的启示
Crit Care Explor. 2020 Apr 29;2(4):e0109. doi: 10.1097/CCE.0000000000000109. eCollection 2020 Apr.
2
Pathogenesis-directed therapy of 2019 novel coronavirus disease.针对 2019 新型冠状病毒病的发病机制导向治疗。
J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10.
3
Molecular Insights into Severe Acute Respiratory Syndrome Coronavirus 2 Pathobiology: Dissecting the Interplay between Cellular Innate Immunity and Immune Evasion.深入了解严重急性呼吸综合征冠状病毒 2 发病机制的分子机制:剖析细胞固有免疫与免疫逃避之间的相互作用。
Crit Rev Immunol. 2020;40(6):485-496. doi: 10.1615/CritRevImmunol.2020035855.
4
Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV.新型冠状病毒 2019-nCoV:流行情况、与 SARS-CoV 和 MERS-CoV 的生物学和临床特征比较。
Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):2012-2019. doi: 10.26355/eurrev_202002_20379.
5
COVID-19: a conundrum to decipher.COVID-19:一个待破译的谜。
Eur Rev Med Pharmacol Sci. 2020 May;24(10):5830-5841. doi: 10.26355/eurrev_202005_21378.
6
Role of Traditional Chinese Medicine in the Management of Viral Pneumonia.中医药在病毒性肺炎管理中的作用
Front Pharmacol. 2020 Oct 22;11:582322. doi: 10.3389/fphar.2020.582322. eCollection 2020.
7
The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China.中国武汉 2019 年新型冠状病毒和流感病毒合并感染肺炎患者的临床特征。
J Med Virol. 2020 Sep;92(9):1549-1555. doi: 10.1002/jmv.25781. Epub 2020 Mar 30.
8
Universal testing for severe acute respiratory syndrome coronavirus 2 in 2 Philadelphia hospitals: carrier prevalence and symptom development over 2 weeks.在费城的 2 家医院进行的严重急性呼吸综合征冠状病毒 2 通用检测:2 周内的携带者流行率和症状发展。
Am J Obstet Gynecol MFM. 2020 Nov;2(4):100226. doi: 10.1016/j.ajogmf.2020.100226. Epub 2020 Sep 11.
9
Severe acute respiratory syndrome coronavirus 2-induced acute aortic occlusion: a case report.严重急性呼吸综合征冠状病毒 2 引起的急性主动脉闭塞:一例报告。
J Med Case Rep. 2021 Mar 2;15(1):112. doi: 10.1186/s13256-021-02692-x.
10
A consideration of publication-derived immune-related associations in Coronavirus and related lung damaging diseases.考虑冠状病毒和相关肺部损伤疾病的基于出版物的免疫相关关联。
J Transl Med. 2020 Aug 3;18(1):297. doi: 10.1186/s12967-020-02472-z.

引用本文的文献

1
Explanatory predictive model for COVID-19 severity risk employing machine learning, shapley addition, and LIME.采用机器学习、Shapley 加法和 LIME 算法对 COVID-19 严重程度风险进行解释性预测模型。
Sci Rep. 2023 Apr 4;13(1):5481. doi: 10.1038/s41598-023-31542-7.
2
On the Origin of Neutrophil Extracellular Traps in COVID-19.新冠病毒感染中中性粒细胞胞外诱捕网的起源
Front Immunol. 2022 Mar 11;13:821007. doi: 10.3389/fimmu.2022.821007. eCollection 2022.
3
The Role of Obesity in the Immunopathogenesis of COVID-19 Respiratory Disease and Critical Illness.肥胖在 COVID-19 呼吸道疾病和危重症发病机制中的作用。
Am J Respir Cell Mol Biol. 2021 Jul;65(1):13-21. doi: 10.1165/rcmb.2020-0236TR.
4
Comparison of clinical characteristics of patients with pandemic SARS-CoV-2-related and community-acquired pneumonias in Hungary - a pilot historical case-control study.比较匈牙利大流行 SARS-CoV-2 相关肺炎和社区获得性肺炎患者的临床特征 - 一项试点历史病例对照研究。
Geroscience. 2021 Feb;43(1):53-64. doi: 10.1007/s11357-020-00294-x. Epub 2020 Nov 11.
5
Clinical Management of Il-6 Driven Cytokine Storm Related to COVID-19 in a Patient with Recent Spinal Cord Stimulator Implants: A Case Report.近期植入脊髓刺激器的新冠肺炎患者中白细胞介素-6驱动的细胞因子风暴的临床管理:一例报告
Anesth Pain Med. 2020 Aug 1;10(4):e104151. doi: 10.5812/aapm.104151. eCollection 2020 Aug.
6
Cytokine profile and disease severity in patients with COVID-19.COVID-19 患者的细胞因子谱与疾病严重程度。
Cytokine. 2021 Jan;137:155323. doi: 10.1016/j.cyto.2020.155323. Epub 2020 Sep 30.
7
Role for Anti-Cytokine Therapies in Severe Coronavirus Disease 2019.抗细胞因子疗法在重症2019冠状病毒病中的作用
Crit Care Explor. 2020 Aug 10;2(8):e0178. doi: 10.1097/CCE.0000000000000178. eCollection 2020 Aug.

本文引用的文献

1
Influenza and Bacterial Coinfection in Adults With Community-Acquired Pneumonia Admitted to Conventional Wards: Risk Factors, Clinical Features, and Outcomes.入住普通病房的社区获得性肺炎成人患者的流感与细菌合并感染:危险因素、临床特征及转归
Open Forum Infect Dis. 2020 Feb 27;7(3):ofaa066. doi: 10.1093/ofid/ofaa066. eCollection 2020 Mar.
2
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19:一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
3
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
4
Diagnosis and Management of First Case of COVID-19 in Canada: Lessons Applied From SARS-CoV-1.加拿大首例 COVID-19 病例的诊断与管理:从 SARS-CoV-1 中吸取的经验教训。
Clin Infect Dis. 2020 Nov 19;71(16):2207-2210. doi: 10.1093/cid/ciaa227.
5
Lymphopenic community acquired pneumonia as signature of severe COVID-19 infection.淋巴细胞减少型社区获得性肺炎作为重症新型冠状病毒肺炎感染的特征
J Infect. 2020 May;80(5):e23-e24. doi: 10.1016/j.jinf.2020.02.029. Epub 2020 Mar 5.
6
Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19).新型冠状病毒病 2019(COVID-19)的临床特征综述。
J Gen Intern Med. 2020 May;35(5):1545-1549. doi: 10.1007/s11606-020-05762-w. Epub 2020 Mar 4.
7
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
8
Covid-19 - Navigating the Uncharted.新冠疫情——探索未知领域。
N Engl J Med. 2020 Mar 26;382(13):1268-1269. doi: 10.1056/NEJMe2002387. Epub 2020 Feb 28.
9
COVID-19-New Insights on a Rapidly Changing Epidemic.《2019冠状病毒病——快速演变疫情的新见解》
JAMA. 2020 Apr 14;323(14):1339-1340. doi: 10.1001/jama.2020.3072.
10
Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies.基于 SARS-CoV 免疫学研究的 COVID-19 冠状病毒(SARS-CoV-2)潜在疫苗靶点的初步鉴定。
Viruses. 2020 Feb 25;12(3):254. doi: 10.3390/v12030254.

病毒性肺炎的临床表现与免疫学及对2019冠状病毒病管理的启示

The Clinical Presentation and Immunology of Viral Pneumonia and Implications for Management of Coronavirus Disease 2019.

作者信息

Darden Dijoia B, Hawkins Russell B, Larson Shawn D, Iovine Nicole M, Prough Donald S, Efron Philip A

机构信息

Department of Surgery, University of Florida College of Medicine, Gainesville, FL.

Department of Medicine, University of Florida College of Medicine, Gainesville, FL.

出版信息

Crit Care Explor. 2020 Apr 29;2(4):e0109. doi: 10.1097/CCE.0000000000000109. eCollection 2020 Apr.

DOI:10.1097/CCE.0000000000000109
PMID:32426751
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7188425/
Abstract

UNLABELLED

This review will briefly examine the clinical presentation and important immunology of viral pneumonia with a focus on severe acute respiratory syndrome coronavirus 2 (coronavirus disease 2019).

DATA SOURCES STUDY SELECTION DATA EXTRACTION AND DATA SYNTHESIS

The most relevant, original and review literature were assessed for inclusion in this review. Sources included the Centers for Disease Control and Prevention, World Health Organization, and PubMed.

CONCLUSIONS

Pneumonia is a leading cause of hospitalization and death worldwide, with viral etiologies being very common. Given the rapidly emerging pandemic associated with the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019, it is important to review the clinical presentation and immunologic changes associated with viral pneumonia. Symptoms of viral pneumonia include common respiratory tract infection symptoms of cough, fever, and shortness of breath. Immunologic changes include up-regulation of airway pro-inflammatory cytokines and pathogen- and damage-associated molecular patterns contributing to cytokine and genomic changes. Coronavirus disease 2019 clinical presentation is typical of viral pneumonia with an increased prevalence of early pulmonary infiltrates and lymphopenia. Principles of early coronavirus disease 2019 management and isolation as well as potential therapeutic approaches to the emerging pandemic are discussed.

摘要

未标注

本综述将简要探讨病毒性肺炎的临床表现及重要免疫学特征,重点关注严重急性呼吸综合征冠状病毒2(2019冠状病毒病)。

数据来源、研究选择、数据提取与数据综合:评估最相关、原创及综述文献以纳入本综述。来源包括疾病控制与预防中心、世界卫生组织及PubMed。

结论

肺炎是全球住院和死亡的主要原因,病毒病因非常常见。鉴于与新型严重急性呼吸综合征冠状病毒2相关的迅速出现的大流行导致2019冠状病毒病,回顾与病毒性肺炎相关的临床表现和免疫变化很重要。病毒性肺炎的症状包括咳嗽、发热和呼吸急促等常见呼吸道感染症状。免疫变化包括气道促炎细胞因子上调以及病原体和损伤相关分子模式导致细胞因子和基因组变化。2019冠状病毒病的临床表现是典型的病毒性肺炎,早期肺部浸润和淋巴细胞减少的发生率增加。讨论了2019冠状病毒病早期管理和隔离原则以及针对新出现大流行的潜在治疗方法。